ABSTRACT
Background The increase in the number of available biologic agents for psoriasis has led to an urgent need to evaluate their associated risk of serious infections to help inform clinical decisions.
Methodology We systematically searched PubMed, Medline, Embase, and Cochrane databases for biologics targeting TNF (adalimumab, etanercept, infliximab, certolizumab pegol), interleukin (IL)-12/23 (ustekinumab), IL-17A (secukinumab, ixekizumab), IL-17RA (brodalumab) and IL-23p19 (guselkumab, risankizumab, and tildrakizumab) for the primary outcome serious infections, at 10– 16 weeks, 1 year and 3 years. Peto’s method (fixed effect model) was used to estimate the pooled odds ratio (OR) in meta-analyses comparing biologics with one another, methotrexate, or placebo.
Results Forty-three publications (49 trials) consisting of 29,724 participants met our inclusion criteria. Serious infections across all studies were low (n=97) at 10–16 weeks and did not show an increased risk with biologic therapies compared with placebo. Seven head-to-head RCTs were identified, most of which showed no significant difference in the risk of serious infections at 10–16 weeks and at 1 year. Adalimumab was not associated with a significant increased risk of serious infections compared with methotrexate in children at 10–16 weeks.
Conclusions Biologics for psoriasis were not associated with an increased risk of serious infections compared with placebo or one another at 10–16 weeks. Longer-term, real-world data with larger sample sizes are warranted.
Competing Interest Statement
ADB consults and lectures for AbbVie, Almirall, Boehringer-Ingleheim, Celgene, Eli Lilly, Janssen-Cilag, Leo Pharma, Novartis and UCB. RTW has received departmental research funding from Abbvie, Anaptys Bio, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Galderma, Leo Pharma, Novartis, Pfizer, Sanofi and UCB and consults or lectures for Abbvie, Eli Lilly, Leo Pharma, Janssen-Cilag, Novartis, Sandoz, Sanofi and UCB. CHS has received departmental research funding from AbbVie, Novartis, Pfizer, Sanofi; Medical Research Council consortium (PSORT) with AbbVie, Celgene, Eli Lilly, Janssen-Cilag, Leo Pharma, Novartis, Pfizer Sanofi and UCB; NIHR with Sobi; European Consortium with Leo Pharma, Pfizer, Sanofi and UCB. RM has received travel grant from Janssen-Cilag. LM, ZZNY, SM, LSE, MCE, CMO, RP, and MFMM have no conflicts of interest to declare.
Funding Statement
This project was supported by the British Association of Dermatologists. ZZNY is funded by a National Institute for Health Research (NIHR) Academic Clinical Lectureship through the University of Manchester. SKM is funded by a Medical Research Council (MRC) Clinical Academic Research Partnership award (MR/T02383X/1). CHS is funded in part by the (MRC MR/L011808/1). The research was supported by the NIHR Biomedical Research Centre (BRC) at King's College London and Guy's and St Thomas' NHS Foundation Trust. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding sources: This project was supported by the British Association of Dermatologists. ZZNY is funded by a National Institute for Health Research (NIHR) Academic Clinical Lectureship through the University of Manchester. SKM is funded by a Medical Research Council (MRC) Clinical Academic Research Partnership award (MR/T02383X/1). CHS is funded in part by the MRC MR/L011808/1. The research was supported by the NIHR Biomedical Research Centre (BRC) at King’s College London and Guy’s and St Thomas’ NHS Foundation Trust. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health.
Declaration of interests: ADB consults and lectures for AbbVie, Almirall, Boehringer-Ingleheim, Celgene, Eli Lilly, Janssen-Cilag, Leo Pharma, Novartis and UCB. RTW has received departmental research funding from Abbvie, Anaptys Bio, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Galderma, Leo Pharma, Novartis, Pfizer, Sanofi and UCB and consults or lectures for Abbvie, Eli Lilly, Leo Pharma, Janssen-Cilag, Novartis, Sandoz, Sanofi and UCB. CHS has received departmental research funding from AbbVie, Novartis, Pfizer, Sanofi; Medical Research Council consortium (PSORT) with AbbVie, Celgene, Eli Lilly, Janssen-Cilag, Leo Pharma, Novartis, Pfizer Sanofi and UCB; NIHR with Sobi; European Consortium with Leo Pharma, Pfizer, Sanofi and UCB. RM has received travel grant from Janssen-Cilag. LM, ZZNY, SM, LSE, MCE, CMO, RP, and MFMM have no conflicts of interest to declare.
Data Availability
N/A